Boston Scientific ends TAVR sales; J&J shares Monarch robot data

Boston Scientific ends TAVR sales; J&J shares Monarch robot data

Boston Scientific said it would halt worldwide sales of its Acurate devices due to “increased clinical and regulatory requirements.”

Boston Scientific withdraws TAVI devices from the market - Cardiovascular News

Boston Scientific has announced the surprise move to cease sales of its Acurate transcatheter aortic valve implantation (TAVI) systems, including the Acurate neo2 and Acurate Prime devices. In a statement, the company said that the decision was taken following discussions with regulators and that it would cease all commercial and clinical activities related to the devices. “Boston Scientific is discontinuing worldwide sales of the Acurate neo2 a…

Boston Scientific Ends TAVR Sales; J&J Shares Monarch Robot Data - Data Intelligence

Boston Scientific said Wednesday it plans to end worldwide sales of its transcatheter aortic valve replacement systems, citing regulatory hurdles. The company will discontinue its Acurate Neo2 and Acurate Prime TAVR systems, which are sold in Europe, and will not pursue Food and Drug Administration approval for the devices.  Boston Scientific said in a regulatory filing that the decision followed recent discussions with regulators, adding that t…

Boston Scientific Discontinues Acurate Neo2 and Acurate Prime TAVR Systems - Cardiac Interventions Today

May 28, 2025—Boston Scientific announced it is discontinuing worldwide sales of the Acurate Neo2 and Acurate Prime transcatheter aortic valve replacement (TAVR) systems. Related commercial, clinical, research and development, and manufacturing activities will cease, advised the company. The company stated that data continue to support the performance of the Acurate valve system when the product’s optimized instructions for use are followed. Howe…